JP2024546497A5 - - Google Patents
Info
- Publication number
- JP2024546497A5 JP2024546497A5 JP2024535848A JP2024535848A JP2024546497A5 JP 2024546497 A5 JP2024546497 A5 JP 2024546497A5 JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024535848 A JP2024535848 A JP 2024535848A JP 2024546497 A5 JP2024546497 A5 JP 2024546497A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- pharmaceutical composition
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025271167A JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Claudin18.2を標的とする抗体―薬物複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551337.8 | 2021-12-17 | ||
| CN202111551337 | 2021-12-17 | ||
| PCT/CN2022/139637 WO2023109953A1 (zh) | 2021-12-17 | 2022-12-16 | 靶向Claudin18.2的抗体-药物偶联物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025271167A Division JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Claudin18.2を標的とする抗体―薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546497A JP2024546497A (ja) | 2024-12-24 |
| JP2024546497A5 true JP2024546497A5 (cg-RX-API-DMAC7.html) | 2025-11-11 |
| JP7796230B2 JP7796230B2 (ja) | 2026-01-08 |
Family
ID=86774867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535848A Active JP7796230B2 (ja) | 2021-12-17 | 2022-12-16 | Claudin18.2を標的とする抗体―薬物複合体 |
| JP2025271167A Pending JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Claudin18.2を標的とする抗体―薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025271167A Pending JP2026053502A (ja) | 2021-12-17 | 2025-12-22 | Claudin18.2を標的とする抗体―薬物複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20250073347A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4450521A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7796230B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240133715A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119173534A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022416272A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242970A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI869741B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023109953A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022416272A1 (en) * | 2021-12-17 | 2024-07-18 | Fortvita Biologics (Singapore) Pte. Ltd. | Antibody-drug conjugate targeting claudin18.2 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| CN119591708A (zh) * | 2023-09-08 | 2025-03-11 | 成都临界点生物科技有限公司 | 抗Claudin18.2人源化单域抗体 |
| WO2025077815A1 (zh) * | 2023-10-11 | 2025-04-17 | 福佑泰生物制药(新加坡)公司 | 靶向Claudin18.2的抗体-药物偶联物联合治疗癌症的方法 |
| TW202532100A (zh) * | 2023-12-22 | 2025-08-16 | 大陸商信達生物製藥(蘇州)有限公司 | 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用 |
| TW202545991A (zh) * | 2024-01-12 | 2025-12-01 | 大陸商信達生物製藥(蘇州)有限公司 | 抗cd28抗體及其用途 |
| WO2026052046A1 (zh) * | 2024-09-06 | 2026-03-12 | 荣昌生物制药(烟台)股份有限公司 | 抗Claudin18.2抗体药物偶联物用于治疗胃癌和/或胃食管结合部腺癌的用途 |
| CN119345386B (zh) * | 2024-10-25 | 2025-12-09 | 华润生物医药有限公司 | 靶向Claudin18.2的抗体药物耦联物及其用途 |
| WO2026120140A1 (en) | 2024-12-05 | 2026-06-11 | Medizinische Universität Wien | Hydroxy cinnamic acid derivatives |
| WO2026124417A1 (en) * | 2024-12-09 | 2026-06-18 | Lepu Biopharma Co., Ltd. | Anti-cdh17 antibody-drug conjugates and uses thereof |
| CN121130103A (zh) * | 2025-11-05 | 2025-12-16 | 上海以岭药业有限公司 | 靶向cldn 18.2的抗体药物偶联物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9580511B2 (en) * | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
| CA3177215C (en) * | 2017-09-29 | 2026-06-09 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| EP3808376A4 (en) * | 2018-06-17 | 2021-09-01 | L&L Biopharma Co., Ltd. | CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF |
| AU2019414968A1 (en) * | 2018-12-27 | 2021-08-12 | Gigagen, Inc. | Anti-PD-1 binding proteins and methods of use thereof |
| KR20210109520A (ko) * | 2018-12-28 | 2021-09-06 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항체 및 이의 용도 |
| EP3950061A4 (en) * | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| CN117731798A (zh) | 2019-06-28 | 2024-03-22 | 泰州复旦张江药业有限公司 | 抗体偶联药物、其中间体、制备方法及应用 |
| CA3147122A1 (en) * | 2019-07-12 | 2021-01-21 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Cldn18.2 antibody and use thereof |
| CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
| AU2020402006A1 (en) | 2019-12-12 | 2022-07-07 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| CA3178855A1 (en) * | 2020-06-19 | 2021-12-23 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| JP7904824B2 (ja) | 2020-09-15 | 2026-08-13 | シンアフィックス ビー.ブイ. | 抗体-エクサテカンコンジュゲート |
| US20240293457A1 (en) * | 2020-12-25 | 2024-09-05 | Innovent Biologics (Suzhou) Co., Ltd. | Claudin18.2 chimeric antigen receptor and use thereof |
| AU2022416272A1 (en) * | 2021-12-17 | 2024-07-18 | Fortvita Biologics (Singapore) Pte. Ltd. | Antibody-drug conjugate targeting claudin18.2 |
-
2022
- 2022-12-16 AU AU2022416272A patent/AU2022416272A1/en active Pending
- 2022-12-16 US US18/719,023 patent/US20250073347A1/en active Pending
- 2022-12-16 TW TW111148546A patent/TWI869741B/zh active
- 2022-12-16 EP EP22906698.0A patent/EP4450521A1/en active Pending
- 2022-12-16 JP JP2024535848A patent/JP7796230B2/ja active Active
- 2022-12-16 CN CN202280083295.6A patent/CN119173534A/zh active Pending
- 2022-12-16 WO PCT/CN2022/139637 patent/WO2023109953A1/zh not_active Ceased
- 2022-12-16 CA CA3242970A patent/CA3242970A1/en active Pending
- 2022-12-16 KR KR1020247023670A patent/KR20240133715A/ko active Pending
-
2025
- 2025-10-31 US US19/376,098 patent/US20260216353A1/en active Pending
- 2025-12-22 JP JP2025271167A patent/JP2026053502A/ja active Pending